Human papillomavirus vaccine - Biogen Idec

Drug Profile

Human papillomavirus vaccine - Biogen Idec

Alternative Names: Cervical cancer vaccine - Biogen Idec; Cervical dysplasia vaccine - Biogen Idec; E7 protein vaccine; HPV 16 vaccine

Latest Information Update: 22 Feb 2011

Price : $50

At a glance

  • Originator Biogen Idec
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Human papillomavirus infections

Most Recent Events

  • 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
  • 20 Jun 2002 Phase-I clinical trials in Human papillomavirus infections in USA (unspecified route)
  • 11 Jun 1999 Preclinical development for Human papillomavirus infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top